Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ReNeuron Announces £33 Million Financing Package

Published: Monday, July 22, 2013
Last Updated: Monday, July 22, 2013
Bookmark and Share
Placing to raise up to £25.35 million, grant package of £7.8 million from Welsh Government and Notice of General Meeting.

ReNeuron Group plc announced that it has raised a total of £33 million in a financing package that transforms the Company’s prospects and helps position it as a global leader in stem cell development.

Highlights
•£25.35 million (before expenses) of firm commitments to be raised through an
oversubscribed placing of 1,014,000,000 Placing Shares at an Issue Price of 2.5p to
fund its therapeutic programmes through Phase II trials and consequent value
inflection.
•£7.8 million to be provided through a grant package from the Welsh Government to
establish a cell manufacturing and development facility in South Wales for late stage
clinical and commercial product requirements. The Company will move its principal
operations to this facility as it is phased in over the next two years.
•Shareholder register transformed with participation of major new life science and
generalist investors, including Invesco, Abingworth and the Wales Life Sciences
Investment Fund LP, alongside existing holders.
•Issue Price represents a 17.4 per cent discount to the closing mid-market price of an
Ordinary Share on 19 July 2013, being the last Business Day prior to this
announcement. Issue Price represents a 3.1 per cent discount to the average midmarket
price for the last 20 Business Days prior to this announcement.
•The Directors have each agreed to subscribe for shares in the Placing, amounting to a
subscription of £110,000 in aggregate.
•Renowned Welsh life sciences entrepreneur, Sir Chris Evans, to be appointed as a nonexecutive
director of the Company upon closing of the Placing.

Completion of the proposed firm Placing is subject inter alia to shareholder approval, which will be sought at a General Meeting of the Company to be held at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH, at 10.30 a.m. on 7 August 2013. Dealings in the New Ordinary Shares issued in the firm Placing are expected to commence shortly thereafter.

A circular providing further details of the Placing will be sent to Shareholders later today. Once it has been posted, a copy of the Circular will be available on the Company’s website at www.reneuron.com.

Update on the Company’s therapeutic programmes

The Company has today announced its preliminary results for the year ended 31 March 2013, within which the Company has given an update on its therapeutic programmes and other activities.

Edwina Hart, the Welsh Government’s Minister for Economy, Science and Transport, said:

"I am delighted to be welcoming ReNeuron to Wales. Cardiff University has always been one of the leading centres in the UK for both stem cell and neuroscience research, which was recently strengthened by the appointment of Professor Yves Barde to the Research Chair in Neurobiology as part of our Sêr Cymru initiative.

"This is the second investment made by the Wales Life Sciences Investment Fund, a key component in our strategy to support the growth of the life sciences sector in Wales – one of our priority sectors with the potential to make a significant contribution to the Welsh economy."

Michael Hunt, Chief Executive Officer of ReNeuron, said:

“We are delighted with the support provided to us in this fundraising, both by the participating institutional investors, including specialists in the life sciences sector, and the Welsh Government. The overall funding package will transform the financial position of our business and its future prospects, and should allow us to take all of our therapeutic programmes through a Phase II proof-of-concept clinical study and to value inflection through commercial deals over the next three years.

“The Welsh grant package also enables us to take control over the manufacture of our stem cell therapy candidates as they get closer to market. We look forward to working with the Welsh Government to become part of a larger advanced-therapy manufacturing initiative to be established in South Wales over the coming years.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ReNeuron Announces First Patient Treated in US Phase I/II Clinical Trial
Company has announced that the first patient has been treated with the Company’s cell therapy candidate for the blindness causing disease RP in a first-in-human US clinical trial.
Thursday, March 17, 2016
ReNeuron Receives Notice of Grant of Key US Patent on its Cell Cryopreservation Technology
Company has announced that it has received a notice of allowance for a key patent application covering its cell cryopreservation technology.
Tuesday, February 09, 2016
Publication of Pre-Clinical Data Relating to ReNeuron’s Exosome Nanomedicine Platform
Data support the potential use of ReNeuron’s exosomes as therapeutic agents and as a delivery system in gene therapy.
Tuesday, January 12, 2016
Non-executive Director Appointment
Company announces appointment of Dr Mike Owen.
Saturday, December 05, 2015
AGM Trading Update
CTX stem cell therapy candidate currently in a UK Phase II clinical trial.
Friday, September 25, 2015
Preliminary Results for the Year Ended 31 March 2015
Appointment of Olav Hellebø as CEO.
Saturday, July 11, 2015
ReNeuron Announces Research Collaboration with Benitec Biopharma
Collaboration using exosomes as delivery system for gene silencing in cancer therapy.
Tuesday, June 23, 2015
FDA Grants Fast Track Designation to ReNeuron’s RP Cell Therapy Candidate
Approval to commence a Phase I/II clinical trial in the US with stem cell therapy candidate for RP.
Saturday, May 23, 2015
Long Term Clinical Data from PISCES Stroke Trial
Long term data continue to show good safety profile and evidence of sustained improvements in neurological status and limb function.
Saturday, April 18, 2015
ReNeuron Files Application to Commence Phase I/II Clinical Trial in the US
IND application to commence clinical trial for retinitis pigmentosa with hRPC therapy candidate.
Tuesday, April 14, 2015
ReNeuron Reconfigures Board
Company further strengthens executive management for next phase of development.
Wednesday, April 08, 2015
ReNeuron Announces Appointment of Chief Executive Officer
Company appoints Olav Hellebø as new CEO.
Tuesday, September 09, 2014
ReNeuron AGM Trading Update
Results from the Phase I study with ReN009 announced in the first half of 2015.
Tuesday, September 09, 2014
Further Data from First Clinical Trial of ReNeuron’s Stem Cell Therapy to be Presented at Stroke Conference
Long term data continue to show good safety profile and evidence of sustained reductions in neurological impairment and spasticity.
Friday, May 16, 2014
ReNeuron Receives UK Regulatory Approvals
Company receive approvals to commence Phase II clinical trial in stroke and Phase I clinical trial in critical limb ischaemia.
Friday, March 28, 2014
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Researchers Find a Gap in the Brain’s Firewall Against Parkinson’s Disease
Researchers at NIH have found mouse study that identified a key player in the progression of the disorder.
Fat Cells That Amplify Nerve Signals in Response to Cold Also Affect Blood Sugar Metabolism
Researchers at UTSW have found that the protein connexin 43 forms cell-to-cell communication channels on the surface of emerging beige fat cells that amplify the signals from those few nerve fibers.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!